Katy L. Simonsen

3.0k total citations · 2 hit papers
19 papers, 2.3k citations indexed

About

Katy L. Simonsen is a scholar working on Genetics, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Katy L. Simonsen has authored 19 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 5 papers in Oncology and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Katy L. Simonsen's work include Genetic Mapping and Diversity in Plants and Animals (7 papers), Evolution and Genetic Dynamics (4 papers) and Genetic Associations and Epidemiology (3 papers). Katy L. Simonsen is often cited by papers focused on Genetic Mapping and Diversity in Plants and Animals (7 papers), Evolution and Genetic Dynamics (4 papers) and Genetic Associations and Epidemiology (3 papers). Katy L. Simonsen collaborates with scholars based in United States, Germany and Australia. Katy L. Simonsen's co-authors include Lauren M. McIntyre, Koen J. F. Verhoeven, Gary A. Churchill, Charles F. Aquadro, Keith A.A. Fox, Stuart J. Connolly, Sonia S. Anand, Salim Yusuf, Jack Hirsh and Shamir R. Mehta and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

Katy L. Simonsen

19 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Implementing false discovery rate control: increasing your power

2005 822 citations Koen J. F. Verhoeven, Katy L. Simonsen et al. Oikos profile →
Properties of statistical tests of neutrality for DNA polymorphism data.

1995 541 citations Katy L. Simonsen, Gary A. Churchill et al. Genetics profile →

Peers

Countries citing papers authored by Katy L. Simonsen

Since Specialization

Citations

This map shows the geographic impact of Katy L. Simonsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katy L. Simonsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katy L. Simonsen more than expected).

Fields of papers citing papers by Katy L. Simonsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katy L. Simonsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katy L. Simonsen. The network helps show where Katy L. Simonsen may publish in the future.

Co-authorship network of co-authors of Katy L. Simonsen

This figure shows the co-authorship network connecting the top 25 collaborators of Katy L. Simonsen. A scholar is included among the top collaborators of Katy L. Simonsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katy L. Simonsen. Katy L. Simonsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	P801: BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA 2023 ·HemaSphere ·Julia Piasecki, Keyur Desai, (unknown), Ethan Thompson, James Pratt, Noopur Raje, Krina K. Patel, Marc S. Raab, Mark Cook, Katy L. Simonsen, Mihaela Popa McKiver, Shari M. Kaiser, Nathan Martin	1
2	Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM). 2023 ·Journal of Clinical Oncology ·Julia Piasecki, Keyur Desai, (unknown), Ethan Thompson, (unknown), Noopur Raje, Krina K. Patel, Marc S. Raab, Mark Cook, Katy L. Simonsen, Mihaela Popa McKiver, Shari M. Kaiser, Nathan Martin	2
3	Multi-arm multi-stage clinical trials for time-to-event outcomes 2021 ·Journal of Biopharmaceutical Statistics ·(unknown), Priyam Mitra, Katy L. Simonsen	1
4	Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). 2021 ·Journal of Clinical Oncology ·Evan J. Lipson, Hussein Tawbi, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, Shivani Srivastava, (unknown), Katy L. Simonsen, Bin Li, Georgina V. Long, F. Stephen Hodi	118
5	The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies 2018 ·European Journal of Cancer ·Katy L. Simonsen, Paula M. Fracasso, Steven H. Bernstein, Megan Wind‐Rotolo, Manish Gupta, (unknown), Timothy P. Reilly, Jim Cassidy	12
6	CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti–LAG-3) in combination with nivolumab (anti–PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma 2018 ·Annals of Oncology ·Evan J. Lipson, Georgina V. Long, Hussein A. Tawbi, Dirk Schadendorf, Victoria Atkinson, Matthew Maurer, Katy L. Simonsen, Christopher Harbison, F. Stephen Hodi	14
7	Effects ofCYP2C19Genotype on Outcomes of Clopidogrel Treatment 2010 ·New England Journal of Medicine ·Guillaume Paré, Shamir R. Mehta, Salim Yusuf, Sonia S. Anand, Stuart J. Connolly, Jack Hirsh, Katy L. Simonsen, Deepak L. Bhatt, Keith A.A. Fox, John W. Eikelboom	378
8	Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes 2008 ·Journal of the American College of Cardiology ·Olga A. Iakoubova, Marc S. Sabatine, Charles M. Rowland, Carmen H. Tong, Joseph J. Catanese, Koustubh Ranade, Katy L. Simonsen, Todd G. Kirchgessner, Christopher P. Cannon, James J. Devlin, Eugene Braunwald	111
9	Association Between ADAMTS1 Matrix Metalloproteinase Gene Variation, Coronary Heart Disease, and Benefit of Statin Therapy 2008 ·Arteriosclerosis Thrombosis and Vascular Biology ·Marc S. Sabatine, Lynn Ploughman, Katy L. Simonsen, Olga A. Iakoubova, Todd G. Kirchgessner, Koustubh Ranade, Zenta Tsuchihashi, Kim E. Zerba, (unknown), Carmen H. Tong, Christopher J. Packard, Marc A. Pfeffer, James J. Devlin, James Shepherd, Hannia Campos, Frank M. Sacks, Eugene Braunwald	38
10	Model Selection in Binary Trait Locus Mapping 2005 ·Genetics ·Cynthia J. Coffman, R. W. Doerge, Katy L. Simonsen, Krista M. Nichols, (unknown), Russell D. Wolfinger, Lauren M. McIntyre	16
11	Adding Confidence to Gene Expression Clustering 2005 ·Genetics ·Brian Munneke, Karen Schlauch, Katy L. Simonsen, William D. Beavis, R. W. Doerge	11
12	Implementing false discovery rate control: increasing your power breakdown → 2005 ·Oikos ·Koen J. F. Verhoeven, Katy L. Simonsen, Lauren M. McIntyre	822
13	Effect of Safety and Environmental Variables on Task Durations in Steel Erection 2005 ·Journal of Construction Engineering and Management ·Javier Irizarry, Katy L. Simonsen, Dulcy M. Abraham	27
14	Genomic Haplotype Blocks May Not Accurately Reflect Spatial Variation in Historic Recombination Intensity 2004 ·Molecular Biology and Evolution ·Koen J. F. Verhoeven, Katy L. Simonsen	5
15	Using Alpha Wisely: Improving Power to Detect Multiple QTL 2004 ·Statistical Applications in Genetics and Molecular Biology ·Katy L. Simonsen, Lauren M. McIntyre	8
16	Circumventing multiple testing: A multilocus Monte Carlo approach to testing for association 2000 ·Genetic Epidemiology ·Lauren M. McIntyre, Eden R. Martin, Katy L. Simonsen, Norman Kaplan	80
17	Statistical tests of neutrality in the age of weak selection 1998 ·Trends in Ecology & Evolution ·Marta L. Wayne, Katy L. Simonsen	75
18	A Markov Chain Model of Coalescence with Recombination 1997 ·Theoretical Population Biology ·Katy L. Simonsen, Gary A. Churchill	41
19	Properties of statistical tests of neutrality for DNA polymorphism data. breakdown → 1995 ·Genetics ·Katy L. Simonsen, Gary A. Churchill, Charles F. Aquadro	541

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact